Business Wire

OCTAPHARMA-AG

Share
European Authorities Approve Lyophilized S/D Treated Plasma OctaplasLG® for Pre-Hospital Transfusion

Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion. The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings.

“The European authorization of octaplasLG® powder continues Octapharma's ongoing commitment to help prevent uncontrolled haemorrhage associated with trauma, which accounts for 30%-50% of all deaths in the first 24 hours"1-5, says Dr. Oliver Hegener, Vice President IBU Critical Care.

Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death. Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic acidosis, that begins soon after injury. Early - pre-hospital - administration of plasma has been shown to increase survival, compared with crystalloids, when pre-hospital transport was longer than 20 minutes.7

Until now, access to early plasma transfusion was limited by logistic hurdles as well as a lack of available transfusion medicine in the pre-hospital setting for both for civilian and military patients.

"octaplasLG® powder, an AB universal plasma, can be stored at room temperature and reconstituted within minutes, representing a potentially lifesaving treatment option in emergency situations and in locations with limited frozen storage facilities and cold chain infrastructure required for regular FFP," explains Dr. Hegener.

About octaplasLG®

Pharmaceutical grade human plasma for infusion with standardised quality and unique pathogen safety profiles due to Octapharma’s integrated pathogen elimination/inactivation concept. The standardised content is achieved by pooling between 630 and 1520 single plasma units from multiple carefully screened donors. Safety measures present during manufacturing include: Donor screening, immunoneutralisation, Solvent/detergent treatment and Ligand affinity chromatography for prion reduction.

The product is approved for:

  • Complex deficiencies of coagulation factors such as coagulopathy due to severe hepatic failure or massive transfusion.
  • Substitution therapy in coagulation factor deficiencies, when a specific coagulation factor concentrate (e.g., factor V or factor XI) is not available for use or in emergency situations when a precise laboratory diagnosis is not possible.
  • Rapid reversal of the effects of oral anticoagulants (coumarin or indanedione type) when a prothrombin complex concentrate is not available for use or administration of vitamin K is insufficient due to impaired liver function or in emergency situations.
  • Potentially dangerous haemorrhages during fibrinolytic therapy, using e.g., tissue plasminogen activators, in patients who fail to respond to conventional measures.
  • Therapeutic plasma exchange procedures, including those in thrombotic thrombocytopenic purpura (TTP).

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care.

Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centres across Europe and the US.

References:

1. Bosch F, Angele MK, Chaudry IH. Gender differences in trauma, shock and sepsis. Mil Med Res. 2018;5(1):35.

2. Iapichino GE, Ponschab M, Cadamuro J, et al. Concentrated lyophilized plasma used for reconstitution of whole blood leads to higher coagulation factor activity, but unchanged thrombin potential compared with fresh-frozen plasma. Transfusion. 2017;57(7):1763-71.

3. Nguyen C, Bordes J, Cungi PJ, et al. Use of French lyophilized plasma transfusion in severe trauma patients is associated with an early plasma transfusion and early transfusion ratio improvement. J Trauma Acute Care Surg. 2018;84(5):780-5.

4. Moore EE, Moore HB, Kornblith LZ, et al. Trauma-induced coagulopathy. Nat Rev Dis Primers. 2021;7(1):30.

5. Johansson PI, Sorensen AM, Perner A, et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care. 2011;15(6): R272.

6. World Health Organization. Injuries and violence. 19 March 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/injuries-and-violence. Last accessed January 2023.

7. Pusateri AE, Moore EE, Moore HB, et al. Association of Prehospital Plasma Transfusion With Survival in Trauma Patients With Hemorrhagic Shock When Transport Times Are Longer Than 20 Minutes: A Post Hoc Analysis of the PAMPer and COMBAT Clinical Trials. JAMA Surg. 2020;155(2): e195085.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005552/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CapVest and Parquest Agree Terms on IPN’s Acquisition of Sopral8.7.2025 10:00:00 CEST | Press release

Inspired Pet Nutrition (“IPN”), the fast-growing pet food company controlled by CapVest Partners LLP (“CapVest”), and Parquest, a leading investment firm, have agreed terms on the acquisition of Sopral, a prominent branded pet food platform serving the European market, with manufacturing operations based in France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708134461/en/ Sopral products The transaction is subject to customary regulatory approvals and closing conditions. Financial terms have not been disclosed. Based in Pléchâtel, Brittany, France, Sopral is a leading manufacturer of branded premium dry petfood with a comprehensive range of high-quality nutritional solutions, including Pro-Nutrition Prestige, Pure Life and Protect brands. Sopral has a strong footprint and reputation in France and a fast growing online and international market presence in over 50 countries around the world. Employing over 130 people, th

Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release

At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release

Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime

Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release

Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha

Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks8.7.2025 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world’s first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata’s proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707682186/en/ [Murata Manufacturing Co., Ltd.] The world’s first high-frequency filter using XBAR technology The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye